zithromax and ST-Elevation-Myocardial-Infarction

zithromax has been researched along with ST-Elevation-Myocardial-Infarction* in 1 studies

Other Studies

1 other study(ies) available for zithromax and ST-Elevation-Myocardial-Infarction

Article	Year
Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. Journal of medical case reports, 2020, Dec-18, Volume: 14, Issue:1 In December 2019, a new coronavirus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) spread from China, causing a pandemic in a very short time. The main clinical presentation of SARS-CoV-2 infection (COVID-19, coronavirus disease-2019) is pneumonia, but several cardiovascular complications may also occur (e.g., acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure and cardiogenic shock). Direct or indirect mechanisms induced by SARS-CoV-2 could be implicated in the pathogenesis of these events.. We report herein the third case of COVID-19 autoimmune haemolytic anaemia (AIHA) reported so far, which occurredwithout any other possible explanations in a Caucasian patient. The patient also suffered from ST-elevation myocardial injury.. Both complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6). Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Asymptomatic Infections; Azithromycin; C-Reactive Protein; Coombs Test; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin-6; Platelet Aggregation Inhibitors; Prednisolone; SARS-CoV-2; ST Elevation Myocardial Infarction	2020

Article

Year

Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report.

Journal of medical case reports, 2020, Dec-18, Volume: 14, Issue:1

In December 2019, a new coronavirus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) spread from China, causing a pandemic in a very short time. The main clinical presentation of SARS-CoV-2 infection (COVID-19, coronavirus disease-2019) is pneumonia, but several cardiovascular complications may also occur (e.g., acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure and cardiogenic shock). Direct or indirect mechanisms induced by SARS-CoV-2 could be implicated in the pathogenesis of these events.. We report herein the third case of COVID-19 autoimmune haemolytic anaemia (AIHA) reported so far, which occurredwithout any other possible explanations in a Caucasian patient. The patient also suffered from ST-elevation myocardial injury.. Both complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6).

Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Asymptomatic Infections; Azithromycin; C-Reactive Protein; Coombs Test; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin-6; Platelet Aggregation Inhibitors; Prednisolone; SARS-CoV-2; ST Elevation Myocardial Infarction

2020